Your Health. Your Family. Your Choice.
Administered by: Other Purchased by: ?
Life Threatening? No
Write-up: Death; This is a spontaneous report downloaded from the Agency regulatory authorities -WEB [Lareb (LRB) number NL-LRB-00459915] from a contactable physician. An 88-year-old male patient received the 2nd dose of bnt162b2 (COMIRNATY) (lot# EJ6790), via an unspecified route of administration, on 24Feb2021, at single dose, for COVID-19 immunisation. Medical history included chronic obstructive pulmonary disease, 2nd degree atrioventricular block, colon cancer (palliative policy), living in nursing home (for 1 year). Concomitant medications included paracetamol (unknown manufacturer), acetylcysteine (unknown manufacturer), bimatoprost, timolol maleate (GANFORT), ipratropium bromide, salbutamol sulfate (COMBIVENT), oxycodone hydrochloride (OXYCODON), citalopram (unknown manufacturer), haloperidol (unknown manufacturer), fluticasone propionate (unknown manufacturer), oxazepam (unknown manufacturer). The patient previously took the 1st dose of Comirnaty for COVID-19 immunisation and experienced no adverse event. The patient experienced death on 28Feb2021. It was not reported if an autopsy was performed.No clinical changes were seen between the vaccination and patient''s death. No follow-up attempts are possible. No further information is expected.; Reported Cause(s) of Death: death
Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166